Literature DB >> 17555470

Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas.

M Ponzoni1, F Berger, C Chassagne-Clement, M Tinguely, A Jouvet, A J M Ferreri, S Dell'Oro, M R Terreni, C Doglioni, J Weis, M Cerati, M Milani, P Iuzzolino, T Motta, A Carbone, E Pedrinis, J Sanchez, J-Y Blay, M Reni, A Conconi, F Bertoni, E Zucca, F Cavalli, B Borisch.   

Abstract

Well-established histopathological prognostic factors are lacking in primary central nervous system (CNS) lymphomas (PCNSL). The present study investigated the presence and prognostic role of tumour necrosis (TN) and reactive perivascular T-cell infiltrate (RPVI), defined as a rim of small reactive T-lymphocytes occurring alone or located between the vascular wall and large neoplastic cells, in tumour samples from 100 immunocompetent patients with PCNSL. World Health Organization histotypes of the patients were: 96 diffuse large B-cell lymphomas, two Burkitt-like lymphomas, one anaplastic large T-cell lymphoma and one unclassified B-cell lymphoma. TN was observed in 24 (24%) cases and RPVI in 26 (36%) of 73 assessable cases. Patients with RPVI-positive lesions exhibited a significantly better overall survival (OS) than patients with RPVI-negative lymphoma, particularly among patients treated with high-dose methotrexate-based chemotherapy (3-year OS: 59 +/- 14% vs. 42 +/- 9%, P = 0.02). By contrast, the presence of TN did not demonstrate prognostic significance. Multivariate analysis confirmed an independent association between RPVI and survival. In conclusion, the presence of RPVI is independently associated with survival in PCNSL. This parameter can be easily and routinely assessed at diagnosis on histopathological specimens.

Entities:  

Mesh:

Year:  2007        PMID: 17555470     DOI: 10.1111/j.1365-2141.2007.06661.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  23 in total

Review 1.  New approaches in primary central nervous system lymphoma.

Authors:  Eleanor Fraser; Katherine Gruenberg; James L Rubenstein
Journal:  Chin Clin Oncol       Date:  2015-03

Review 2.  Primary central nervous system lymphoma: essential points in diagnosis and management.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2017-03-17       Impact factor: 3.064

3.  Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression.

Authors:  Seung-Myoung Son; Sang-Yun Ha; Hae-Yong Yoo; Dongryul Oh; Seok-Jin Kim; Won-Seog Kim; Young-Hyeh Ko
Journal:  Mod Pathol       Date:  2016-09-30       Impact factor: 7.842

Review 4.  Biology of CNS lymphoma and the potential of novel agents.

Authors:  James L Rubenstein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 5.  The Challenge of Primary Central Nervous System Lymphoma.

Authors:  Julia Carnevale; James L Rubenstein
Journal:  Hematol Oncol Clin North Am       Date:  2016-12       Impact factor: 3.722

6.  Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma.

Authors:  Miaoxia He; Changjing Zuo; Jianjun Wang; Jianmin Liu; Binghua Jiao; Jianmin Zheng; Zailong Cai
Journal:  Neuro Oncol       Date:  2013-03-12       Impact factor: 12.300

Review 7.  Insights into the biology of primary central nervous system lymphoma.

Authors:  Maciej M Mrugala; James L Rubenstein; Maurilio Ponzoni; Tracy T Batchelor
Journal:  Curr Oncol Rep       Date:  2009-01       Impact factor: 5.075

8.  Corticosteroid pre-treated primary CNS lymphoma: a detailed analysis of stereotactic biopsy findings and consideration of interobserver variability.

Authors:  Evrim Önder; Ata T Arıkök; Sevgen Önder; Ünsal Han; Mehmet Sorar; Hayri Kertmen; Engin D Yılmaz; Ramazan Fesli; Murat Alper
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

9.  Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.

Authors:  Shinji Nakashima; Yasuo Sugita; Hiroaki Miyoshi; Fumiko Arakawa; Hiroko Muta; Yukinao Ishibashi; Daisuke Niino; Koichi Ohshima; Mizuhiko Terasaki; Yukihiko Nakamura; Motohiro Morioka
Journal:  J Neurooncol       Date:  2015-12-08       Impact factor: 4.130

Review 10.  Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.

Authors:  M Ponzoni; S Issa; T T Batchelor; J L Rubenstein
Journal:  Ann Oncol       Date:  2013-11-20       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.